Mesoblast Announces FDA Clears IND Filing by Partner Teva to Commence Phase 3 CHF Trial
October 30, 2013 at 18:57 PM EDT
Regenerative medicine company Mesoblast Limited (OTC: MBLTY ) today announced that the United States Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) filing made by Mesoblast's development and commercial partner Teva Pharmaceutical Industries (NASDAQ: TEVA ) to commence a Phase 3 trial in patients
